NIAID Site Search

Eric O. Long, Ph.D., is the Chief of the Molecular and Cellular Immunology Section. The main interest of our lab has been the molecular basis of the regulation of human natural killer (NK) cell function in the context of different stimuli and the contribution of activating and inhibitory receptors to intracellular signals that dictate NK cell reactivity.

Last Reviewed: June 23, 2022

Last Reviewed: August 6, 2024

Last Reviewed: August 6, 2024

Sample application from David Al-Adra MD, Ph.D., for NIH standard independent research project grant (K08).

Last Reviewed: September 13, 2024

Last Reviewed: August 6, 2024

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study.

Published: October 20, 2022

Last Reviewed: August 6, 2024

Last Reviewed: August 6, 2024

By studying the rare disease APECED, NIAID researchers and colleagues uncovered an unexpected immune mechanism that promotes susceptibility to fungal infections of the mucous membranes. Their findings suggest potential therapies for people with APECED and pave the way for work to investigate these tissue-specific immune responses in other diseases.

Last Reviewed: January 14, 2021

NIAID requires your human subjects research plans to include women, minorities, and participants of all ages unless you can justify their exclusion.

Last Reviewed: January 24, 2022

Last Reviewed: August 6, 2024

Last Reviewed: August 6, 2024

Two U.S. Food and Drug Administration (FDA)–approved mRNA vaccines for COVID-19 have saved millions of lives. These vaccines were developed with NIH support and research on a protein found on SARS-CoV-2, the virus that causes COVID-19. Clinical trials for the COVID-19 vaccines in people were established in what seemed like record time. But in reality, more than 50 years of public and private

Last Reviewed: April 4, 2024

Create a winning application by keeping your NIH peer reviewers in mind as you anticipate questions about your project's significance and innovation.

Published: February 17, 2021

Information about the importance of starting and staying on antiretroviral treatment for HIV management from NIAID.

Last Reviewed: November 27, 2018

It's a fact of grant life: most applications do not succeed. If yours is one of them at NIH, you need to first spend some time identifying what went wrong.

Last Reviewed: September 13, 2024

Office of Research on Women’s Health and NIH Support for Research on Women’s Health Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2019–2020 508-compliant PDF

Last Reviewed: March 8, 2022

National Institutes of Health // Food and Drug Administration // Immunology Interest Group

Last Reviewed: June 8, 2023

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002

Michail Lionakis, M.D., Sc.D., is Chief of the Laboratory of Clinical Immunology and Microbiology and the Chief of the Fungal Pathogenesis Section. The section's research focuses on 1) cellular and molecular factors that regulate the immune response against mucosal and invasive candidiasis and invasive aspergillosis in clinically relevant animal models and 2) better understanding the genetic and immune defects that underlie enhanced susceptibility to mucocutaneous and invasive fungal infections in humans.

Last Reviewed: February 18, 2025

Information for NIAID grant recipients about how to apply for a renewal to continue funding.

Last Reviewed: November 15, 2023

Resources for NIAID grantees about the first events that occur after applications go through peer review and are approved for funding.

Last Reviewed: December 18, 2019

Sample application from Mohammad Ayoub Mir

Last Reviewed: August 4, 2017

Ian A. Myles, M.D., M.P.H., is the Staff Clinician for the Epithelial Therapeutics Unit. The unit focuses on how human health is affected by the normal microorganisms that live on our skin (collectively termed the microbiome). Our emphasis is on eczema (also called atopic dermatitis or AD), which is an inflammatory disease of the skin associated with reduced quality of life and high risk of developing asthma, allergic rhinitis, and food allergies.

Last Reviewed: November 29, 2023